DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Altman Advisors Inc.

Altman Advisors Inc. increased its stake in DexCom, Inc. (NASDAQ:DXCMFree Report) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 13,574 shares of the medical device company’s stock after buying an additional 264 shares during the period. Altman Advisors Inc.’s holdings in DexCom were worth $1,684,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of DXCM. Valley National Advisers Inc. grew its holdings in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. MV Capital Management Inc. grew its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares during the last quarter. Smithfield Trust Co grew its holdings in shares of DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares during the last quarter. Washington Trust Advisors Inc. grew its holdings in shares of DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after acquiring an additional 193 shares during the last quarter. Finally, NBC Securities Inc. purchased a new position in shares of DexCom during the third quarter valued at $47,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total value of $79,411.25. Following the transaction, the executive vice president now owns 68,212 shares in the company, valued at $8,611,765. The disclosure for this sale can be found here. In the last 90 days, insiders sold 190,004 shares of company stock valued at $25,610,270. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on DXCM shares. Canaccord Genuity Group lifted their price target on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Raymond James lifted their price target on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Finally, Citigroup lifted their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $141.67.

Read Our Latest Report on DXCM

DexCom Stock Up 3.0 %

Shares of NASDAQ:DXCM traded up $3.74 on Wednesday, reaching $129.71. The company had a trading volume of 2,306,275 shares, compared to its average volume of 2,931,835. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The stock has a 50-day moving average price of $133.44 and a 200 day moving average price of $122.57. The stock has a market capitalization of $51.58 billion, a P/E ratio of 83.68, a P/E/G ratio of 2.13 and a beta of 1.23. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCMGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. On average, equities analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

About DexCom

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.